Monte Carlo calculated TG‐60 dosimetry parameters for the  emitter  brachytherapy source

Sadeghi, Mahdi; Taghdiri, Fatemeh; Hamzeh, Hosseini Seyed; Tenreiro, Claudio

doi:10.1118/1.3488971

Cited by 15 publications

(4 citation statements)

References 19 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7, the radial dose function of the

^{90} Y

glass seed is compared to those of the several beta‐emitter seeds. ( 7 , 22 , 23 , 28 , 29 ) As observed in figure, the radial dose function of this seed is approximately similar to those of the

^{90} Sr false/^{90} normalY

, and

^{142} Pr

seeds. Also, the decrease in radial dose function for that is slower than to those of the

^{153} Sm,^{32} P

, and

^{114} In

sources.…”

Section: Resultssupporting

confidence: 68%

See 1 more Smart Citation

Monte Carlo characterization of biocompatible beta‐emitting glass seed incorporated with the radionuclide as a SPECT marker for brachytherapy applications

Hadadi

Sadeghi

Sardari

et al. 2013

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

A glass seed consisting of the β−‐emitting radionuclide 90Y incorporated with radionuclide 153Sm as SPECT marker is proposed for potential application in brachytherapy in order to reduce the undesirable dose to healthy adjacent organs. The aim of this work is to determine the dosimetric characteristics, as suggested in the AAPM TG‐60/TG‐149 reports, for this seed using Monte Carlo simulation. Monte Carlo codes MCNP5, EGSnrc, and FLUKA were used to calculate the absorbed dose distribution around the seed. Dosimetric parameters, such as reference absorbed dose rate, radial dose function, and one‐dimensional (1D) and two‐dimensional (2D) anisotropy functions, were obtained. The computational results from these three codes are in agreement within 5.4% difference on average. The absorbed dose rate at the reference point was estimated to be 5.01 cGy normalh−1 μCi−1 and self absorption of YAS glass seed amounted to 30.51%. The results showed that, with thermal neutron bombardment of 5 hours in a typical flux, sufficient activity for applications in brachytherapy may be achieved. With a 5 mCi initial activity, the total dose of a YAS glass seed was estimated to be 1.38 Gy at 1.0 cm from the seed center. Comparing with gamma emitting seeds, the 90Y seed could reduce undesirable doses to adjacent organs, because of the rapid dose falloff of beta ray. Because of the high R90 value of 5.5 mm, fewer number of 90Y seeds will be required for an interstitial brachytherapy treatment using permanent implant, in comparison with other beta‐emitting seeds. The results would be helpful in the development of the radioactive implants using 90Y glass seeds for the brachytherapy treatment.PACS numbers: 87.53.Jw, 87.56.bg

show abstract

“…7, the radial dose function of the

^{90} Y

glass seed is compared to those of the several beta‐emitter seeds. ( 7 , 22 , 23 , 28 , 29 ) As observed in figure, the radial dose function of this seed is approximately similar to those of the

^{90} Sr false/^{90} normalY

, and

^{142} Pr

seeds. Also, the decrease in radial dose function for that is slower than to those of the

^{153} Sm,^{32} P

, and

^{114} In

sources.…”

Section: Resultssupporting

confidence: 68%

“…Figure 1 illustrates the sample of desired glass seed. Because of high density of YAS glass, a radio‐opaque marker is not necessary; however, the 103 keV gamma ray emitted by

^{153} Sm

can be detected by a gamma camera (23) . Also, cladding or encapsulation is not required because the seed is nonreactive in water or tissue.…”

Section: Methodsmentioning

confidence: 99%

Monte Carlo characterization of biocompatible beta‐emitting glass seed incorporated with the radionuclide as a SPECT marker for brachytherapy applications

Hadadi

Sadeghi

Sardari

et al. 2013

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides, cladding or encapsulation is not required because the seed is unreactive in water or tissue [15]. Furthermore, in one of our previous papers [41], we evaluated dose distribution of the 153 Sm and 142 Pr source for brachytherapy. The MCNP5 Monte Carlo code was used to calculate the quantitative dosimetric parameters suggested in the AAPM TG-60 reports in ranges of millimeters [42].…”

Section: Radiobiological Characteristicsmentioning

confidence: 99%

Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy

Bakht

Sadeghi²

2011

Ann Nucl Med

Self Cite

View full text Add to dashboard Cite

Radionuclides of rare earth elements are gaining importance as emerging therapeutic agents in nuclear medicine. β(-)-particle emitter 142Pr [T (1/2) = 19.12 h, E(-)β = 2.162 MeV (96.3%), Eγ = 1575 keV (3.7%)] is one of the praseodymium-141 (100% abundant) radioisotopes. Production routes and therapy aspects of 142Pr will be reviewed in this paper. However, 142Pr produces via 141Pr(n, γ) 142Pr reaction by irradiation in a low-fluence reactor; 142Pr cyclotron produced, could be achievable. 142Pr due to its high β(-)-emission and low specific gamma γ-emission could not only be a therapeutic radionuclide, but also a suitable radionuclide in order for biodistribution studies. Internal radiotherapy using 142Pr can be classified into two sub-categories: (1) unsealed source therapy (UST), (2) brachytherapy. UST via 142Pr-HA and 142Pr-DTPA in order for radiosynovectomy have been proposed. In addition, 142Pr Glass seeds and 142Pr microspheres have been utilized for interstitial brachytherapy of prostate cancer and intraarterial brachytherapy of arteriovenous malformation, respectively.

show abstract

“… 6 , 27 – 29 These bioglasses interact with the surrounding tissue in situ and can be absorbed by body after about 7 months. 19 , 21 , 30 …”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Proposed Biodegradable 188Re Source for Brachytherapy Application

2015

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate dosimetric characteristics based on Monte Carlo (MC) simulations for a proposed beta emitter bioglass 188Re seed for internal radiotherapy applications.The bioactive glass seed has been developed using the sol-gel technique. The simulations were performed for the seed using MC radiation transport code to investigate the dosimetric factors recommended by the AAPM Task Group 60 (TG-60).Dose distributions due to the beta and photon radiation were predicted at different radial distances surrounding the source. The dose rate in water at the reference point was calculated to be 7.43 ± 0.5 cGy/h/μCi. The dosimetric factors consisting of the reference point dose rate, D(r0,θ0), the radial dose function, g(r), the 2-dimensional anisotropy function, F(r,θ), the 1-dimensional anisotropy function, φan(r), and the R90 quantity were estimated and compared with several available beta-emitting sources.The element 188Re incorporated in bioactive glasses produced by the sol-gel technique provides a suitable solution for producing new materials for seed implants applied to brachytherapy applications in prostate and liver cancers treatment. Dose distribution of 188Re seed was greater isotropic than other commercially attainable encapsulated seeds, since it has no end weld to attenuate radiation.The beta radiation-emitting 188Re source provides high doses of local radiation to the tumor tissue and the short range of the beta particles limit damage to the adjacent normal tissue.

show abstract

Monte Carlo calculated TG‐60 dosimetry parameters for the emitter brachytherapy source

Cited by 15 publications

References 19 publications

Monte Carlo characterization of biocompatible beta‐emitting glass seed incorporated with the radionuclide as a SPECT marker for brachytherapy applications

Monte Carlo characterization of biocompatible beta‐emitting glass seed incorporated with the radionuclide as a SPECT marker for brachytherapy applications

Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy

Evaluation of a Proposed Biodegradable 188Re Source for Brachytherapy Application

Contact Info

Product

Resources

About